Follicular mycosis fungoides: a case report and review of the literature

DeBloom, James R.; Severson, Jessica L.; Gaspari, Anthony A.; Scott, Glynis

doi:10.1034/j.1600-0560.2001.028006318.x

Cited by 16 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidermotropism involving the interfollicular epidermis has also been observed in folliculotropic MF. [18][19][20][21] Mucinous degeneration of the follicular epithelia has always been considered a very typical and defining feature of so-called ''MF-associated follicular mucinosis.'' [22][23][24][25][26][27] However, as previously reported, follicular mucinosis in folliculotropic MF is not a constant feature.…”

Section: Discussionmentioning

confidence: 99%

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

Muniesa

Estrach

Pujol³

et al. 2010

Journal of the American Academy of Dermatology

108

121

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

Muniesa

Estrach

Pujol³

et al. 2010

Journal of the American Academy of Dermatology

108

121

View full text Add to dashboard Cite

“…3 There is scant information in the literature regarding its clinical manifestations. [4][5][6][7][8][9][10][11][12][13][14][15][16] Data regarding optimal therapies in FMF are similarly limited. In addition, only 2 other studies have provided any survival data for patients with FMF.…”

Section: Discussionmentioning

confidence: 99%

Folliculotropic Mycosis Fungoides

Gerami

Rosen²,

Kuzel³

et al. 2008

Arch Dermatol

196

View full text Add to dashboard Cite

To study the clinical features, therapeutic responses, and outcomes in patients with folliculotropic mycosis fungoides (FMF) and to compare our single-center experience of 43 patients with the findings from the Dutch Cutaneous Lymphoma Group.Setting: A single-center experience from the Northwestern University Multidisciplinary Cutaneous Lymphoma Group.Patients: Forty-three patients with FMF were included in the study and compared with 43 age-and stagematched patients with classic epidermotropic mycosis fungoides (MF) with similar follow-up time.Results: Folliculotropic mycosis fungoides showed distinct clinical features, with 37 patients having facial involvement (86%) and only 6 having lesions limited to the torso (14%). The morphologic spectrum of lesions is broad and includes erythematous papules and plaques with follicular prominence with or without alopecia; comedonal, acneiform, and cystic lesions; alopecic patches with or without scarring; and nodular and prurigolike lesions. Sixty-five percent of patients had alopecia, which in 71% of cases involved the face. Severe pruritus was seen in 68% of patients. In general, patients responded poorly to skin-directed therapy and in almost all cases required systemic agents to induce even a partial remission, including patients with early-stage disease. Overall survival was poor. Patients with early-stage disease (ՅIIA) had a 10-year survival of 82%, which took a steep drop off to 41% by 15 years. Patients with late-stage disease (ՆIIB) had an outcome similar to those patients in the control group with conventional epidermotropic MF of a similar stage. Conclusions:The morphologic spectrum of clinical presentation for FMF is broad and distinct from those in conventional MF. This is at least partially attributed to the ability of FMF to simulate a variety of inflammatory conditions afflicting the follicular unit. The disease course is aggressive, and many patients, including those with early disease, show a poor outcome particularly between 10 and 15 years after the initial onset of disease. Response to skindirected therapy is poor even in early-stage disease, and our best results were seen with psoralen plus UV-A (PUVA) therapy with oral bexarotene or PUVA with interferon alfa. These findings corroborate those of the Dutch Cutaneous Lymphoma Group and further validate the classification of FMF as a distinct entity.

show abstract

“…27,36 Lesions initially show an acneiform or comedo-like aspect, or one with milia en plaque , follicular papules, follicular keratosis, erythematous plaques, papular or alopecic plaques (alopecia mucinosa), including mucin secretion (mucinorrhea). 5,26-33 …”

Section: Mycosis Fungoides Clinical Variants Described In the "Who-ementioning

confidence: 99%

Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update

Yamashita

Abbade

Marques

et al. 2012

An. Bras. Dermatol.

View full text Add to dashboard Cite

This paper reviews the diagnostic and classificatory concepts of mycosis fungoides and Sézary syndrome in light of the latest normative publications. It describes the great variability of the clinical expression of mycosis fungoides in its early stages as well as the histopathological and immunohistochemical aspects that help with diagnosis. The diagnostic criteria required for characterizing Sézary syndrome and the staging system used for both mycosis fungoides and Sézary syndrome are described.

show abstract

Follicular mycosis fungoides: a case report and review of the literature

Abstract: Our case is discussed in the context of previously reported cases of follicular MF; we also include a review of all cases of follicular MF published to date that meet the strict criterion for this diagnosis.

Cited by 16 publications

References 22 publications

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

Folliculotropic Mycosis Fungoides

Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update

Contact Info

Product

Resources

About